

Resource Summary Report

Generated by [kravitz2](#) on Aug 9, 2026

Human CXCL10/IP-10/CRG-2 Antibody

RRID:AB_354433

Type: Antibody

Proper Citation

R and D Systems Cat# AF-266-NA, RRID:AB_354433

Antibody Information

URL: http://antibodyregistry.org/AB_354433

Proper Citation: R and D Systems Cat# AF-266-NA, RRID:AB_354433

Target Antigen: CXCL10/IP-10/CRG-2

Host Organism: Goat

Clonality: polyclonal

Comments: Applications: ELISA, Immunohistochemistry, Neutralization, Intracellular Staining by Flow Cytometry, Immunocytochemistry, CyTOF-ready

Antibody Name: Human CXCL10/IP-10/CRG-2 Antibody

Description: This polyclonal targets CXCL10/IP-10/CRG-2

Target Organism: Human

Antibody ID: AB_354433

Vendor: R and D Systems

Catalog Number: AF-266-NA

Alternative Catalog Numbers: AF-266-SP

Record Creation Time: 20250820T001745+0000

Record Last Update: 20250820T075328+0000

Ratings and Alerts

- Independent validation by the NYU Langone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Human CXCL10/IP-10/CRG-2 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Suarez-Carmona M, et al. (2026) Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer. Signal transduction and targeted therapy, 11(1).

Jiang SS, et al. (2023) Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell host & microbe, 31(5), 781.